Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1225341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Shan Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Oxazolidinones, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
To evaluate contezolid (MRX-I) antibacterial activity against Mycobacterium abscessus in vitro and in vivo and to assess whether MRX-I treatment can prolong survival of infected zebrafish.
Methods
MRX-I inhibitory activity against M. abscessus in vitro was assessed by injecting MRX-I into zebrafish infected with green fluorescent protein-labelled M. abscessus . Thereafter, infected zebrafish were treated with azithromycin (AZM), linezolid (LZD) or MRX-I then maximum tolerated concentrations (MTCs) of drugs were determined based on M. abscessus growth inhibition using one-way ANOVA. Linear trend analysis of CFU counts and fluorescence intensities (mean ± SE values) was performed to detect linear relationships between MRX-I, AZM and LZD concentrations and these parameters.
Results
MRX-I anti- M. abscessus minimum inhibitory concentration (MIC) and MTC were 16 μg/mL and 15.6 μg/mL, respectively. MRX-I MTC-treated zebrafish fluorescence intensities were significantly lower than respective LZD group intensities (whole-body: 439040 ± 3647 vs. 509184 ± 23064, p < 0.01); head: 74147 ± 2175 vs. 95996 ± 8054, p < 0.05). As MRX-I concentration was increased from 0.488 μg/mL to 15.6 μg/mL, zebrafish whole-body, head and heart fluorescence intensities decreased. Statistically insignificant differences between the MRX-I MTC group survival rate (78.33%) vs. corresponding rates of the 62.5 μg/mL-treated AZM MTC group (88.33%, p > 0.05) and the 15.6 μg/mL-treated LZD MTC group (76.67%, p > 0.05) were observed.
Conclusion
MRX-I effectively inhibited M. abscessus growth and prolonged zebrafish survival when administered to M. abscessus -infected zebrafish, thus demonstrating that MRX-I holds promise as a clinical treatment for human M. abscessus infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
- Tuberculosis Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Tuberculosis Department, Hengshui Third People's Hospital, Hengshui, China.
- Tuberculosis Department, Henan Province Anyang City Tuberculosis Prevention and Control Institute, Anyang, China.
- Tuberculosis Department, Zhengzhou Sixth People's Hospital, Zhengzhou, China.
- Tuberculosis Department, Hohhot Second Hospital, Hohhot, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Gao, S., Nie, W., Liu, L., Su, L., You, Y., Geng, R., & Chu, N. (2023). Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1225341
Vancouver
Gao S, Nie W, Liu L, Su L, You Y, Geng R, et al. Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1225341
BibTeX
@article{Gao2023,
author = {Gao, Shan and Nie, Wenjuan and Liu, Lina and Su, Lei and You, Yingxia and Geng, Ruixue and Chu, Naihui},
title = {Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1225341}
}
EUVIMED